A randomized prospective trial of ioxagl
โ
Andrew G.C. Sutton; Victoria J. Ashton; Philip G. Campbell; Dallas J.A. Price; J
๐
Article
๐
2002
๐
John Wiley and Sons
๐
English
โ 63 KB
## Abstract We performed a randomized, prospective, double blind trial comparing the use of the ionic dimer contrast agent ioxaglate 320 (Hexabrix) with the nonionic dimer contrast agent iodixanol 320 (Visipaque) in 618 patients undergoing percutaneous coronary intervention (PCI) for stable or unst